why is eveyone so unhappy?, page-8

Phase 3 comparison of Artimist to IV , due Jan 2013. Group of 150+ intensive care sick kids in Africa.

After Papua New Guinea trial, pre-clinical, comparison to therapies before that advanced intensive stage, multi-injection etc. Wouldn't be surprised if the OZ government didn't help out with the study...

The method is highly promising, relatively fast bioavailability whichhas to be good in treating the increasing load, don't see why it shouldn't also be better than those therapies either. Better tolerated, less chance of complication or error.